Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect

Oxurion is left with one last shot at success. The latest drug candidate to flounder in the clinic is THR-687, a pan RGD integrin antagonist that failed a midphase eye disease trial, dragging Oxurion’s stock down 40% to 0.60 euro cents ($0.63).